Reply to: ‘EFNA3 is a prognostic biomarker for the overall survival of patients with hepatocellular carcinoma’
Open Access
- 20 May 2022
- journal article
- letter
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (3) , 880-882
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- EFNA3 is a prognostic biomarker for the overall survival of patients with hepatocellular carcinomaJournal of Hepatology, 2022
- Ephrin-A3/EphA2 axis regulates cellular metabolic plasticity to enhance cancer stemness in hypoxic hepatocellular carcinomaJournal of Hepatology, 2022
- Effects of hypoxia‐inducible factor‐1α and hypoxia‐inducible factor‐2α overexpression on hepatocellular carcinoma survival: A systematic review with meta‐analysisJournal of Gastroenterology and Hepatology, 2021
- Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β‐catenin‐EGFR‐PI3K‐Akt‐mTOR signaling pathwayMolecular Carcinogenesis, 2017
- Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletionGut, 2010
- Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cellsOncogene, 2008
- Human Hepatitis B Virus X Protein Is a Possible Mediator of Hypoxia-Induced Angiogenesis in HepatocarcinogenesisBiochemical and Biophysical Research Communications, 2000